Prevention of Postmenopausal Osteoporosis

Changes in bone mineral density with age, menopausal status and body mass index in Turkish women

OBJECTIVE

The aim was to evaluate changes in bone mineral density (BMD) with age and body mass index (BMI) in healthy pre- and postmenopausal women living in the urban areas of Turkey.

DESIGN

The study was prospective, carried out from 1993 to 1997.

SETTING

The study carried out at a university hospital, the Istanbul University Cerrahpasa School of Medicine, Turkey.

PATIENTS

The study group consisted of 849 healthy women of ages 20-84 years, admitted to the Istanbul University Cerrahpasa School of Medicine. The cases were divided into age groups, starting with 20-29 years and ending with 70 years and over. For regression analysis, the cases were further regrouped as 20-39, 40-59 and 60 years and over. Dual energy X-ray absorptiometry (DEXA) was used to measure BMD in the lumbar vertebrae (L2-L4) and in the classical locations of the proximal femur such as the femoral neck, the Ward's triangle and the trochanter. Multiple regression analysis was performed for the evaluation of annual changes in BMD with respect to age and/or BMI.

RESULTS

A significant decrease in BMD started especially in the 40-49 age group, matching the average age of menopause in the study population. In contrast to the non-significant changes in the 20-39 age group, a significant decrease in BMD in the 40-59 age group, which included the average age of menopause, was detected in all locations (p < 0.0001). In addition to the significant effect of the menopause on BMD, an association between BMD and BMI was found in every location and age group (p = 0.02 to p < 0.0001). The total bone loss in the 70 and over age group, in comparison with the 30-39 age group, was 18.78% in L2-L4, 21.69% in the femoral neck, 32.68% in the Ward's triangle and 14.11% in the trochanter. Corresponding values between age groups 70 and over and 60-69 were 0.25%, 7.62%, 11.94% and 8.29%, respectively. Women in the older age groups had a slower decline in BMD in the lumbar vertebrae, in comparison with the proximal femur. Moreover, the maximum postmenopausal total bone mineral loss was in the Ward's triangle.

CONCLUSIONS

The present results, confirming the results of other studies, have revealed a significant association between BMD and the menopausal status of women in the Turkish population. Additionally, a significant correlation has been detected between BMI and BMD, regardless of location and age.

Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women

OBJECTIVE

To investigate the effects of a hormone replacement therapy regime of continuous oestrogen and interrupted progestogen, administered transdermally, on the endometrium of postmenopausal women, the pattern of bleeding and relief of menopausal symptoms.

DESIGN

Volunteer pilot study of up to six months duration involving weekly application of an oestrogen-only skin patch releasing 50 microg oestradiol per day interspersed with a combined oestrogen and progestogen patch releasing 50 microg oestradiol and 250 microg norethisterone acetate per day for three days. Transvaginal ultrasound measurements of endometrial thickness and endometrial biopsies were performed in the third month of treatment at the end of both an oestrogen-only phase of treatment and a combined oestrogen-progestogen phase.

SETTING

Specialist community menopause clinic, Dean Terrace Centre, Edinburgh.

PARTICIPANTS

Fifteen healthy postmenopausal women.

MAIN OUTCOME MEASURES

Effect of treatment on endometrial histology, the immunolocalisation of oestrogen and progesterone receptors and the cell proliferation marker Ki 67 after three months of treatment and the proportion of women without bleeding at six months.

RESULTS

Treatment provided relief of hot flushes and by the sixth month of study 10 of the 14 women who completed treatment had no vaginal bleeding (71%). No endometrial hyperplasia or atypical changes were observed in biopsies and ultrasound measurements of endometrial thickness demonstrated a thin endometrium. Reduced immunostaining for Ki 67 was observed in endometrium from the combined phase of treatment compared with the oestrogen-only phase, consistent with a progestogenic-antagonism of proliferation. Exposure to progestogen did not suppress steroid receptors as similar immunostaining was observed in both treatment phases.

CONCLUSIONS

Continuous oestrogen and interrupted progestogen administered transdermally offers promise as a novel bleed-free hormone replacement therapy for postmenopausal women.

Very low estrogen-desogestrel contraceptive in perimenopausal hormonal replacement

New oral contraceptives (OC) with lower estrogen contents are potentially useful for menopausal replacement. An OC with 20 micrograms ethinyl estradiol and 150 micrograms desogestrel was used for this purpose in perimenopausal women with climacteric syndrome. The treated group (N = 30), was given OC for 6 months. The control group (N = 29) was kept under observation. Serum FSH, luteinizing hormone, estradiol, cholesterol, HDL-cholesterol and triglycerides were measured. OC treatment induced prompt and clear relief of the climacteric syndrome. Endogenous serum estradiol was greatly reduced with treatment. Serum cholesterol, initially high in relation to young women, diminished with OC treatment, while HDL-cholesterol increased, significantly reducing the cholesterol/HDL-cholesterol ratio. This possibly beneficial estrogen effect was apparently not counteracted by desogestrel (a nearly non-androgenic progestogen). The initially high triglycerides were not modified by the OC. Cyclical bleeding was induced in all treated women, no atypical endometrial hyperplasia was found. This lower estrogen OC preparation may be a good alternative for estrogen replacement in perimenopausal women; its contraceptive properties may strongly appeal those needing fertility control.

Estrogen replacement therapy and osteoporosis

Estrogen cannot replace bone that has been lost nor...straighten curvature of the spine or restore lost height. Usually, however, it can arrest the disease's progression.

Estrogen-progestogen replacement and cancer risk

The increasing popularity of hormone replacement has focused renewed attention on the issue of whether certain sex steroids predispose to--or exert a protective effect against--various forms of carcinoma. In particular, the impact of the sex hormones on the pathogenesis of breast cancer remains highly controversial. Published reports have failed to demonstrate a clear relationship.

Estrogen replacement after menopause. When is it warranted?

As longevity increases, so will the number of women living for many years beyond menopause. The estrogen deprivation that occurs at menopause results in many degenerative changes in a woman's body, some of which cause unpleasant or disabling symptoms. To maintain good health and vitality in menopausal and postmenopausal women, serious consideration should be given to appropriate estrogen replacement therapy. Although such therapy has some risks, the benefits appear to exceed the risks.

Climacteric symptoms among women aged 60-62 in Linköping, Sweden, in 1986

By means of a simple postal questionnaire, all women aged 60, 61 and 62 (n = 2015) living in the community of Linköping, Sweden, were screened for vasomotor symptoms and local vaginal complaints. After one reminder, answers were received from 73% of the women. At the time of the survey (April 1986) all the women were post-menopausal, the median period since menopause being 11 yr. Slightly over one in four of the women (27%) were suffering from sweating and hot flushes. Ten percent (10%) of the women who were more than 15 yr post-menopausal still had moderate to severe climacteric symptoms. Vasomotor symptoms were significantly more common among oophorectomized women than among those whose ovaries were intact. Local vaginal symptoms were positively correlated with urinary problems, repeated urinary tract infections and a high risk of disturbance of sexual activity. It was concluded that climacteric symptoms often persist for more than 15 yr after the menopause.